頭頸椎鱗狀細胞癌 (HNSCC) :KOL的洞察
Head and Neck Squamous Cell Carcinoma: KOL Insight
|頭頸椎鱗狀細胞癌 (HNSCC) :KOL的洞察 Head and Neck Squamous Cell Carcinoma: KOL Insight|
|出版日期: 2016年03月01日||內容資訊: 英文||
本報告以頭頸椎鱗狀細胞癌 (HNSCC) 為主題，提供北美、歐洲的KOL的見解，上市藥、開發平台藥物詳細調查。
Key opinion leaders (KOLs) say immunotherapies will transform head and neck squamous cell carcinoma (HNSCC) treatment. But until Phase III trial results are in, no one knows exactly where these promising new drugs will fit into the treatment algorithm-and whether any one brand can corner the market.
Find out what KOLs think in FirstWord's new report, KOL Insight: HNSCC
You'll find out how immunotherapies are likely to be used, how they'll affect current treatments, and whether they'll face competition from targeted agents in the pipeline. You'll also get KOLs' candid thoughts on the important clinical trials shaping HNSCC treatment and prescribing.
Plus: Order the report today and you'll receive three quarterly FirstWord Therapy Trends Update Bulletins absolutely free!